Molecular typing relies on molecular genetic tests and is not still routinely obtainable. Molecular subtypes and immunohistochemical surrogate markers with the tumors (HR, HER2, triple unfavorable) correlate in about 70%. The differentiation of luminal A and B subtypes by HR position and proliferation markers like Ki-67 may be helpful, https://tariqh776hzq6.ssnblog.com/profile